✦ LIBER ✦

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

✍ Scribed by Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven

Book ID: 117308817
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 211 KB
Volume: 378
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)60983-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rilpivirine versus efavirenz with tenofo

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

✍ Jean-Michel Molina; Pedro Cahn; Beatriz Grinsztejn; Adriano Lazzarin; Anthony Mi 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 210 KB

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB

First-line antiretroviral therapy with a

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 276 KB

Ritonavir-boosted lopinavir plus nucleos

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 311 KB

Switching to coformulated elvitegravir,

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

✍ Pozniak, Anton; Markowitz, Martin; Mills, Anthony; Stellbrink, Hans-Juergen; Ant 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 274 KB